- Home
- Europe Medicinal Chemistry For Drug Discovery Market
Europe Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-334 | No of pages: 162 | Format:
Europe medicinal chemistry for drug discovery market is projected to register a substantial CAGR of 13.7% in the forecast period of 2022 to 2029.The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Europe Medicinal Chemistry For Drug Discovery Market, By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products, Others), Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases, Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes, Others), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe medicinal chemistry for drug discovery market are:
Rising interest in biologics
Increase in research and development investment for discovery and development of novel drug molecules for rare diseases
Market Players:
The key market players for Europe medicinal chemistry for drug discovery market are listed below:
Eurofins Scientific
Labcorp Drug Development
WuXi AppTec
Evotec SE
Pfizer Inc.
Sygnature Discovery
Thermo Fisher Scientific, Inc.
Charles River
Certara Inc
Domainex
Genscript Biotech
Aurigene Pharmaceutical Services
Malvern Panalytical Ltd (Parent Company Spectris PLC)
Aurelia Biosciences Ltd.
Taros Chemical GmBH & Co. KG
Selvita
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 16 1.1 OBJECTIVES OF THE STUDY 16 1.2 MARKET DEFINITION 16 1.3 OVERVIEW OF EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 16 1.4 CURRENCY AND PRICING 18 1.5 LIMITATIONS 18 1.6 MARKETS COVERED 19 2 MARKET SEGMENTATION 21 2.1 MARKETS COVERED 21 2.2 GEOGRAPHICAL SCOPE 22 2.3 YEARS CONSIDERED FOR THE STUDY 23 2.4 DBMR TRIPOD DATA VALIDATION MODEL 24 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27 2.6 MULTIVARIATE MODELLING 28 2.7 MARKET END USER COVERAGE GRID 29 2.8 PROCESS LIFELINE CURVE 30 2.9 DBMR MARKET POSITION GRID 31 2.10 VENDOR SHARE ANALYSIS 33 2.11 SECONDARY SOURCES 34 2.12 ASSUMPTIONS 34 3 EXECUTIVE SUMMARY 35 4 PREMIUM INSIGHTS 38 4.1 PESTEL ANALYSIS 39 4.2 POTERS FIVE FORCES 40 5 EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 41 6 MARKET OVERVIEW 42 6.1 DRIVERS 44 6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 44 6.1.2 RISE IN CHRONIC DISEASES 44 6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 45 6.1.4 GROWTH IN BIOLOGICS 45 6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 45 6.2 RESTRAINTS 46 6.2.1 RISE IN COST OF FORMULATED DRUG 46 6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 46 6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 47 6.3 OPPORTUNITIES 47 6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 47 6.3.2 RISE IN HEALTHCARE EXPENDITURE 47 6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 48 6.4 CHALLENGES 48 6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 48 6.4.2 STRINGENT REGULATIONS 49 7 IMPACT OF COVID-19 ON EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 50 7.1 IMPACT ON PRICE 50 7.2 IMPACT ON DEMAND 50 7.3 IMPACT ON SUPPLY CHAIN 51 7.4 STRATEGIC DECISIONS BY MANUFACTURERS 51 7.5 CONCLUSION 52 8 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 53 8.1 OVERVIEW 54 8.2 TARGET SELECTION 57 8.3 TARGET VALIDATION 57 8.4 HIT-TO-LEAD IDENTIFICATION 57 8.5 LEAD OPTIMIZATION 58 8.6 CANDIDATE VALIDATION 58 9 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 59 9.1 OVERVIEW 60 9.2 FRAGMENT-BASED VARIATION 63 9.3 STRUCTURE BASED DRUG DESIGN 63 9.4 DIVERSITY ORIENTED SYNTHESIS 64 9.5 CHEMOGENOMICS 64 9.6 NATURAL PRODUCTS 64 9.7 OTHERS 65 10 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 66 10.1 OVERVIEW 67 10.2 SMALL MOLECULES 70 10.3 BIOLOGICS 70 11 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 71 11.1 OVERVIEW 72 11.2 ONCOLOGY 75 11.3 NEUROLOGY 75 11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 76 11.5 CARDIOVASCULAR DISEASES 76 11.6 DIGESTIVE SYSTEM DISEASES 77 11.7 OTHERS 77 12 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 78 12.1 OVERVIEW 79 12.2 CONTRACT RESEARCH ORGANIZATION 82 12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 82 12.4 ACADEMIC AND RESEARCH INSTITUTES 83 12.5 OTHERS 83 13 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY COUNTRY 84 13.1 EUROPE 84 13.1.1 GERMANY 92 13.1.2 FRANCE 94 13.1.3 U.K. 96 13.1.4 ITALY 98 13.1.5 SPAIN 100 13.1.6 NETHERLANDS 102 13.1.7 RUSSIA 104 13.1.8 SWITZERLAND 106 13.1.9 BELGIUM 108 13.1.10 TURKEY 110 13.1.11 AUSTRIA 112 13.1.12 NORWAY 114 13.1.13 HUNGARY 116 13.1.14 LITHUANIA 118 13.1.15 IRELAND 120 13.1.16 POLAND 122 13.1.17 REST OF EUROPE 124 14 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 125 14.1 COMPANY SHARE ANALYSIS: EUROPE 125 15 SWOT ANALYSIS 126 16 COMPANY PROFILE 127 16.1 EUROFINS SCIENTIFIC 127 16.1.1 COMPANY SNAPSHOT 127 16.1.2 REVENUE ANALYSIS 128 16.1.3 COMPANY SHARE ANALYSIS 128 16.1.4 SERVICE PORTFOLIO 128 16.1.5 RECENT DEVELOPMENT 129 16.2 LABCORP DRUG DEVELOPMENT 130 16.2.1 COMPANY SNAPSHOT 130 16.2.2 REVENUE ANALYSIS 131 16.2.3 COMPANY SHARE ANALYSIS 131 16.2.4 SERVICE PORTFOLIO 132 16.2.5 RECENT DEVELOPMENT 132 16.3 CHARLES RIVER 133 16.3.1 COMPANY SNAPSHOT 133 16.3.2 REVENUE ANALYSIS 133 16.3.3 COMPANY SHARE ANALYSIS 134 16.3.4 SERVICE PORTFOLIO 134 16.3.5 RECENT DEVELOPMENTS 134 16.4 WUXI APPTEC 135 16.4.1 COMPANY SNAPSHOT 135 16.4.2 REVENUE ANALYSIS 135 16.4.3 COMPANY SHARE ANALYSIS 136 16.4.4 SERVICE PORTFOLIO 136 16.4.5 RECENT DEVELOPMENTS 136 16.5 EVOTEC SE 137 16.5.1 COMPANY SNAPSHOT 137 16.5.2 REVENUE ANALYSIS 137 16.5.3 COMPANY SHARE ANALYSIS 138 16.5.4 SERVICE PORTFOLIO 138 16.5.5 RECENT DEVELOPMENTS 138 16.6 PIRAMAL PHARMA SOLUTIONS 139 16.6.1 COMPANY SNAPSHOT 139 16.6.2 SERVICE PORTFOLIO 139 16.6.3 RECENT DEVELOPMENTS 139 16.7 THERMO FISHER SCIENTIFIC INC. 140 16.7.1 COMPANY SNAPSHOT 140 16.7.2 REVENUE ANALYSIS 140 16.7.3 SERVICE PORTFOLIO 141 16.7.4 RECENT DEVELOPMENT 141 16.7.4.1 ACQUISITION 141 16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 142 16.8.1 COMPANY SNAPSHOT 142 16.8.2 REVENUE ANALYSIS 142 16.8.3 SERVICE PORTFOLIO 143 16.8.4 RECENT DEVELOPMENT 143 16.9 AURELIA BIOSCIENCES 144 16.9.1 COMPANY SNAPSHOT 144 16.9.2 SERVICE PORTFOLIO 144 16.9.3 RECENT DEVELOPMENTS 144 16.10 BIOBLOCKS INC 145 16.10.1 COMPANY SNAPSHOT 145 16.10.2 SERVICE PORTFOLIO 145 16.10.3 RECENT DEVELOPMENT 145 16.11 CERTARA INC 146 16.11.1 COMPANY SNAPSHOT 146 16.11.2 REVENUE ANALYSIS 146 16.11.3 SERVICE PORTFOLIO 147 16.11.4 RECENT DEVELOPMENTS 147 16.12 DOMAINEX 148 16.12.1 COMPANY SNAPSHOT 148 16.12.2 SERVICE PORTFOLIO 148 16.12.3 RECENT DEVELOPMENT 148 16.13 GENSCRIPT BIOTECH 149 16.13.1 COMPANY SNAPSHOT 149 16.13.2 REVENUE ANALYSIS 149 16.13.3 SERVICE PORTFOLIO 150 16.13.4 RECENT DEVELOPMENT 150 16.14 PFIZER INC. 151 16.14.1 COMPANY SNAPSHOT 151 16.14.2 REVENUE ANALYSIS 151 16.14.3 SERVICE PORTFOLIO 152 16.14.4 RECENT DEVELOPMENTS 152 16.15 SELVITA 153 16.15.1 COMPANY SNAPSHOT 153 16.15.2 REVENUE ANALYSIS 153 16.15.3 SERVICE PORTFOLIO 154 16.15.4 RECENT DEVELOPMENTS 154 16.15.4.1 ACQUISITION 154 16.16 SPECTRIS PLC 155 16.16.1 COMPANY SNAPSHOT 155 16.16.2 REVENUE ANALYSIS 155 16.16.3 SERVICE PORTFOLIO 156 16.16.4 RECENT DEVELOPMENT 156 16.17 SYGNATURE DISCOVERY 157 16.17.1 COMPANY SNAPSHOT 157 16.17.2 SERVICE PORTFOLIO 157 16.17.3 RECENT DEVELOPMENTS 157 16.18 TAROS CHEMICAL GMBH 158 16.18.1 COMPANY SNAPSHOT 158 16.18.2 SERVICE PORTFOLIO 158 16.18.3 RECENT DEVELOPMENT 158 17 QUESTIONNAIRE 159 18 RELATED REPORTS 162Segmentation
Short Description Europe Medicinal Chemistry for Drug Discovery Market, By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization and Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products and Others), Drug Type (Small Molecules and Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases and Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes and Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2029 Market Definition: Medicinal chemistry is the interdisciplinary field of science that involves a team of scientists (including synthetic organic chemists, analytical chemists, biologists, toxicologists, pharmacologists, microbiologists, and biopharmacists) working together for drug discovery, design, development and synthesis of new pharmaceuticals. Moreover, the contribution of medicinal chemistry is not confined just to the discovery stage. It carries its purpose along the entire spectrum of clinical development. Each and every stage of clinical development involves surplus amounts of formulated drugs for studying potential benefits in human trials. With time the chemical methods adopted for the discovery of the molecules have also undergone changes leading to the development of technologies such as combinatorial chemistry (combichem), microwave assisted organic synthesis (MAOS) and high-throughput (HTS) biological screening. Market Segmentation: Europe medicinal chemistry for drug discovery market is categorized into five notable segment which is process, design, drug type, therapeutic area and end user. On the basis of process, the Europe medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. In 2022, target selection segment is expected to dominate the Europe medicinal chemistry for drug discovery market as it is the first process from where the drug discovery begins and where the biological targets are selected in an area of unmet medical needs. On the basis of design, the Europe medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, natural products and others. In 2022, the fragment based variation segment is expected to dominate the Europe medicinal chemistry for drug discovery market due to the fact that many potent compounds/ inhibitors of diverse targets have been developed using this method. On the basis of drug type, the Europe medicinal chemistry for drug discovery market is segmented into small molecules and biologics. In 2022, small molecules segment is expected to dominate the market due to the fact that as per the market study most of the drug discovery organizations are highly focused on small molecules discovery and less focused on biologics including proteins, peptides among others. On the basis of therapeutic area, the Europe medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease and others. In 2022, oncology segment is expected to dominate the market due to increasing prevalence of cancer and increasing number of clinical trials and research & development activities for development of novel therapeutics. On the basis of end user, the Europe medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical & biotechnology companies and others. In 2022, contract research organization is expected to dominate in the Europe medicinal chemistry for drug discovery market because major market players signs collaborative agreement with contract research organizations for ongoing clinical trials in order to attain early drug development and approval. Market Players The key market players for Europe medicinal chemistry for drug discovery market are listed below: Eurofins Scientific Labcorp Drug Development WuXi AppTec Evotec SE Pfizer Inc. Sygnature Discovery Thermo Fisher Scientific, Inc. Charles River Certara Inc Domainex Genscript Biotech Aurigene Pharmaceutical Services Malvern Panalytical Ltd (Parent Company Spectris PLC) Aurelia Biosciences Ltd. Taros Chemical GmBH & Co. KG SelvitaMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.